Alerta

Vera Therapeutics Inc. (VERA)

NasdaqGM: VERA · Precio en tiempo real · USD

32.28

+0.65 (2.06%)

Al cierre: Aug 18, 2026, 3:59 PM

2.06% (1D)

Precio de compra	n/a
Capitalización de mercado	2.33B
Ingresos (TTM)	n/a
Beneficio neto (TTM)	-401.9M
Beta	0.95
EPS (TTM)	-5.99
Ratio PER (TTM)	n/a
Adelante PE	-7.31
P/B (TTM)	5.70
P/S (TTM)	n/a
Earnings Date	Nov 5, 2026

Precio de venta	n/a
Volumen	1,013,349
Volumen medio (20D)	1,961,464
Abierto	31.31
Anterior Cerrar	31.63
Rango del día	31.31 - 32.35
Rango de 52 semanas	21.15 - 56.05
analista	Strong Buy
Precio objetivo	79 (144.73%)
Dividendos	n/a
Fecha ex dividendo	n/a

Acerca de VERA

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immuno...

[Leer más]

Industria Biotechnology

Sector Healthcare

IPO Fecha May 14, 2021

Empleados 361

Bolsa de Valores NasdaqGM

Símbolo bursátil VERA

Sitio web https://veratx.com

Perfil completo de la empresa

Desempeño financiero

En 2025, los ingresos de Vera Therapeutics fueron 0, un aumento de undefined% en comparación con 0 del año anterior. Las ganancias fueron -299.62M, un aumento de 96.92%.

Estados financieros

Pronóstico del analista

Según las calificaciones de los analistas de 14, la calificación promedio de las acciones de VERA es "Strong Buy". El pronóstico del precio de las acciones a 12 meses es 79, que es Potencial alcista de 144.73% del último precio.

Previsiones bursátiles

Sorpresa de resultados

Vera Therapeutics ha publicado sus resultados trimestrales en Aug 10, 2026:

Ingresos de $0 falla las estimaciones por $0, con NaN% Crecimiento interanual.

EPS de -1.52 supera las estimaciones en 0.07, con -26.67% Disminución interanual.

Próxima publicación de resultados

Está previsto que Vera Therapeutics Inc. publique sus resultados el Nov 5, 2026, durante el horario de mercado.
Los analistas proyectan ingresos de ... Actualizar

Noticias

1 mes hace · MarketBeat

Vera Therapeutics Wins FDA Approval for TRUTAKNA in IgA Nephropathy, Sets Launch

Vera Therapeutics (NASDAQ:VERA) said the U.S. Food and Drug Administration granted accelerated approval to TRUTAKNA, or atacicept-vymj, for adults with primary IgA nephropathy at risk for disease prog...

1 mes hace · Simply Wall St.

Is FDA Accelerated Approval Of TRUTAKNA Transforming The Investment Case For Vera Therapeutics (VERA)?

Vera Therapeutics recently received FDA accelerated approval for TRUTAKNA™ (atacicept-vymj), a first-in-class dual BAFF/APRIL inhibitor to reduce proteinuria in adults with primary IgA nephropathy at ...

1 mes hace · Simply Wall St.

Vera Therapeutics (VERA) Could Be 92% Below Fair Value After FDA Approval

Vera Therapeutics (VERA) has drawn fresh attention after the US Food and Drug Administration granted accelerated approval for TRUTAKNA to treat adults with IgA nephropathy who are at risk for disease ...

1 mes hace · Simply Wall St.

Vera Therapeutics (VERA) Stock Looks Fully Valued After Its 185% Run

Vera Therapeutics has delivered a strong 184.9% return over the past 5 years, yet its valuation checks and current market multiples point to a stock that may now be leaning expensive rather than clear...

1 mes hace · MT Newswires

Sector Update: Healthcare Stocks Gain Late Afternoon

Healthcare stocks were higher late Tuesday afternoon, with the NYSE Healthcare Index and the State S

Página 1 de 2

Vera Therapeutics Inc. (VERA)